Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 318 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $76.99, for a total value of $24,482.82. Following the completion of the transaction, the president now owns 1,443,002 shares in the company, valued at approximately $111,096,723.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Stephen Hoge also recently made the following trade(s):

• On Thursday, August 29th, Stephen Hoge sold 300 shares of Moderna stock. The shares were sold at an average price of $78.03, for a total value of $23,409.00.
• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The shares were sold at an average price of $84.10, for a total value of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.45 during mid-day trading on Wednesday, hitting $72.49. The company had a trading volume of 4,230,645 shares, compared to its average volume of 4,090,974. The company has a market capitalization of $27.78 billion, a price-to-earnings ratio of -4.63 and a beta of 1.67. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock's 50-day moving average price is $102.13 and its 200-day moving average price is $112.97.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analysts' expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm's quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.62) earnings per share. On average, sell-side analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent research reports. Oppenheimer raised their target price on Moderna from $163.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, June 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research report on Thursday, August 1st. Piper Sandler reaffirmed an "overweight" rating and set a $157.00 price target (down from $214.00) on shares of Moderna in a research report on Friday, August 2nd. Royal Bank of Canada downgraded Moderna from an "outperform" rating to a "sector perform" rating and decreased their price target for the company from $125.00 to $90.00 in a research report on Monday, August 5th. Finally, The Goldman Sachs Group decreased their price target on Moderna from $204.00 to $178.00 and set a "buy" rating for the company in a research report on Friday, August 2nd. Ten analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $123.79.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the second quarter valued at $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the fourth quarter valued at $27,000. Cedar Wealth Management LLC boosted its stake in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. bought a new stake in Moderna during the first quarter valued at $32,000. Finally, Family Firm Inc. bought a new stake in Moderna during the second quarter valued at $33,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.